Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Klotho Neurosciences develops innovative cell and gene therapies targeting age-related neurodegenerative diseases like Alzheimer's and ALS. Its proprietary platforms include gene therapy approaches to increase Klotho protein levels, aiming to prevent neuronal decline and improve cognitive function. The company also licenses biosimilar biologics and generic drugs for cancer treatment, focusing on advancing therapies that address aging and chronic diseases in global markets.
This description was generated via AI from an annual report. Updated about 1 year ago.